AB

Ambrosia Biosciences at ObesityWeek 2026

Nov 14–17, 2026 National Harbor, MD ~4.4k attendees Website

Ambrosia Biosciences brings 2 presentations to ObesityWeek 2026 in National Harbor. Its program centres on the discovery of oral small molecule drugs for obesity. It covers AMB-895, a long-acting GLP-1 receptor agonist, and the nonclinical profile of AMB-131, a GIP receptor antagonist.

OrganizationObesityWeek 2026 Attendance
AB
Ambrosia Biosciences
Biotech
Drug developer working on oral small-molecule GLP-1 and GIP receptor agonists for obesity.
Poster
Sun Nov 15
2:30pm–3:30pm
Discovery of AMB-895, a Long-Acting and Novel, Oral Small Molecule GLP-1 Receptor Agonist
Obesity pharmacotherapy and drug developmentInterventional and clinical studies
Poster
Sun Nov 15
2:30pm–3:30pm

Explore the full ObesityWeek 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in National Harbor. Leave your work email and we’ll be in touch.

Privacy

Download the full ObesityWeek 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Find decision makers at Ambrosia Biosciences

Tell us what you sell and we’ll find the people at Ambrosia Biosciences most likely to buy it.

  • Who to contact
  • Their contact info
  • What to say
  • Free, no sign-up

Not affiliated with or endorsed by The Obesity Society (TOS), ObesityWeek® or the American Society for Metabolic and Bariatric Surgery (ASMBS). Submit a correction